4 completed, 2 recruiting, 1 active not recruiting, 1 available. 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Thyroid Dyshormonogenesis 2A: new trials by email Literature Review of Thyroid Dyshormonogenesis 2A trials Research Report on Thyroid Dyshormonogenesis 2A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy Aleeto - Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA | Early Phase 1 | Recruiting | Beijing Tiantan Hospital | 20 | 2025-05-31 | 2025-09-03 |
| Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease RT-QuIC | Recruiting | Xuanwu Hospital, Beijing | 458 | 2023-05-01 | 2026-03-27 | |
| Safinamide for Multiple System Atrophy (MSA) Safinamide Methanesulfonate, Safinamide Methanesulfonate matching placebo - Multiple System Atrophy | Phase 2 | Completed | Zambon SpA | 49 | 2019-10-29 | 2021-10-13 |
| Early Check: Expanded Screening in Newborns Confirmatory Testing - Spinal Muscular Atrophy, Fragile X Syndrome | Active not recruiting | RTI International | 30000 | 2018-10-15 | 2026-07-01 | |
| AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients AZD3241, Placebo - Multiple System Atrophy, MSA | Phase 2 | Completed | AstraZeneca | 59 | 2015-04-27 | 2017-09-25 |
| Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism Data collection - Atypical Parkinsonism, Dementia With Lewy Bodies | Completed | Rambam Health Care Campus | 8 | 2013-11-01 | 2024-01-12 | |
| Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins intravenous immunoglobulin (IVIg) - Multiple System Atrophy | Phase 2 | Completed | University of Massachusetts, Worcester | 9 | 2008-06-01 | 2017-02-23 |
| "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy." HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells - Multiple System Atrophy | Available | Hope Biosciences Research Foundation | 2026-04-17 |
Multiple System Atrophy (6) · 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (1) · 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (1) · 3-methylcrotonyl CoA carboxylase 1 deficiency (1) · 3-methylcrotonyl CoA carboxylase 2 deficiency (1) · Acidemia, isovaleric (1) · Acrodermatitis enteropathica (1) · Adenine phosphoribosyltransferase deficiency (1) · Adrenal hyperplasia, congenital, type 5 (1) · Adrenocorticotropic hormone deficiency (1) · Amaurosis congenita of Leber, type 2 (1) · Anemia, Sickle Cell (1) · Angelman Syndrome (1) · Aortic Stenosis, Supravalvular (1)
Basal Ganglia Diseases (7) · Brain Diseases (7) · Central Nervous System Diseases (7) · Movement Disorders (7) · Nervous System Diseases (7) · Neurodegenerative Diseases (7) · Autonomic Nervous System Diseases (6) · Primary Dysautonomias (6) · Synucleinopathies (6) · Mental Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Abnormalities, Multiple (1) · Albinism (1) · Albinism, Oculocutaneous (1)
AZD3241 (1) · Data Collection (1) · Immunoglobulins, Intravenous (1) · safinamide (1)
AstraZeneca (1) · Beijing Tiantan Hospital (1) · Hope Biosciences Research Foundation (1) · RTI International (1) · Rambam Health Care Campus (1) · University of Massachusetts, Worcester (1) · Xuanwu Hospital, Beijing (1) · Zambon SpA (1)
United States (4) · China (2) · Italy (2) · Austria (1) · Finland (1) · France (1) · Israel (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Charlotte Keywood, MD (1) · Curt Scharfe, MD, PhD (1) · Peter Novak, MD, PhD (1) · Tao Feng, M.D. (1) · Yilong Wang, M.D. (1)
PMID 23116538, PMID 31315600, PMID 35142618
2018 (1)